论文部分内容阅读
目的:检测c-Met蛋白、微血管密度在非小细胞肺癌(NSCLC)中的表达,探讨c-Met蛋白表达与预后的关系。方法:运用免疫组织化学SP法对98例NSCLC组织中的c-Met进行检测,用CD34单克隆抗体(mAb)检测微血管密度。结果:c-Met在NSCLC中阳性表达率为63.3%(62/98),Ⅰ～Ⅱ期阳性率为53.6%低于Ⅲ-Ⅳ期阳性率76.2%(P<0.05);c-Met表达与组织学类型、分化程度、年龄、性别均无关(P>0.05)。CD34标记的MVD平均为36.53±10.70条,其中c-Met阴性组28.94±9.62条明显低于c-Met阳性组40.94±8.68条,t检验示P=0.01。Kaplan-Meier生存分析显示:c-Met阴性组1年、3年、5年生存率分别为100%、86.1%、63.9%阳性组分别为75.8%、46.8%、17.7%(P=0.000);Ⅰ-Ⅱ期1年、3年、5年生存率分别为100.0%,78.6%,50.0%;Ⅲ-Ⅳ期1年、3年、5年生存率分别为64.3%,38.1%,14.3%(P=0.01);与性别、年龄、组织类型、分化程度无关(P>0.05)。COX回归分析,c-Met表达及TNM分期均为独立的预后因素(P=0.01)。结论:c-Met的表达与NSCLC的血管形成密切相关,并且是一种预后不良指标。
Objective: To detect the expression of c-Met protein and microvessel density in non-small cell lung cancer (NSCLC) and to explore the relationship between c-Met protein expression and prognosis. Methods: Immunohistochemical SP method was used to detect c-Met in 98 cases of NSCLC tissues. Microvessel density was detected by CD34 monoclonal antibody (mAb). Results The positive rate of c-Met expression in NSCLC was 63.3% (62/98). The positive rate of c-Met was 53.6% in stage Ⅰ-Ⅱ and lower than that in stage Ⅲ-Ⅳ (76.2%, P <0.05) Histological type, degree of differentiation, age and gender (P> 0.05). The average MVD of CD34 markers was 36.53 ± 10.70, of which, 28.94 ± 9.62 in c-Met negative group was significantly lower than 40.94 ± 8.68 in c-Met positive group, t test showed P = 0.01. Kaplan-Meier survival analysis showed that the 1-year, 3-year and 5-year survival rates in c-Met negative group were 100%, 86.1% and 63.9% respectively, which were 75.8%, 46.8% and 17.7%, respectively. The 1-year, 3-year and 5-year survival rates of stage Ⅰ-Ⅱ were 100.0%, 78.6% and 50.0% respectively. The 1-year, 3-year and 5-year survival rates of stage Ⅲ-Ⅳ were 64.3%, 38.1% and 14.3% P = 0.01). There was no correlation with sex, age, type of tissue and differentiation (P> 0.05). COX regression analysis, c-Met expression and TNM staging were independent prognostic factors (P = 0.01). Conclusion: The expression of c-Met is closely related to the angiogenesis of NSCLC and is a poor prognostic indicator.